Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma

Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Megumi, Chamoto, Kenji, Higuchi, Keiko, Yamashita, Saya, Noda, Kenta, Iino, Takuya, Miura, Masahiro, Yamasaki, Toshinari, Ogawa, Osamu, Sonobe, Makoto, Date, Hiroshi, Hamanishi, Junzo, Mandai, Masaki, Tanaka, Yoshimasa, Chikuma, Shunsuke, Hatae, Ryusuke, Muto, Manabu, Minamiguchi, Sachiko, Minato, Nagahiro, Honjo, Tasuku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626008/
https://www.ncbi.nlm.nih.gov/pubmed/31300681
http://dx.doi.org/10.1038/s41598-019-46548-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626008/
https://www.ncbi.nlm.nih.gov/pubmed/31300681
http://dx.doi.org/10.1038/s41598-019-46548-3

Ejemplares similares